Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Health-related quality of life among adult patients with cancer in Uganda - a cross-sectional studyGlobal health action, 2024-12, Vol.17 (1), p.2325728-2325728 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1654-9716 ;ISSN: 1654-9880 ;EISSN: 1654-9880 ;DOI: 10.1080/16549716.2024.2325728 ;PMID: 38596846Full text available |
|
2 |
Material Type: Article
|
The Effectiveness of 23-valent Pneumococcal Polysaccharide Vaccine on Elderly Colorectal Cancer Long-Term Survivors: A population-based exact-matched cohort studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2350093-2350093 [Peer Reviewed Journal]EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2350093 ;PMID: 38744302Full text available |
|
3 |
Material Type: Article
|
An analysis of reported cases shoulder injury related to vaccine administration of after COVID-19 vaccinationHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2321672-2321672 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2321672 ;PMID: 38439670Full text available |
|
4 |
Material Type: Article
|
COVID-19 clinical trial participation and awareness in TexasHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2340692-2340692 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2340692 ;PMID: 38658140Full text available |
|
5 |
Material Type: Article
|
Herpes zoster in older adults: Impact on carbon footprint in the United StatesHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2335722-2335722 [Peer Reviewed Journal]2024 GSK. Published with license by Taylor & Francis Group, LLC. 2024 GSK ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2335722 ;PMID: 38698759Full text available |
|
6 |
Material Type: Article
|
Lung mucosal immunity to NTHi vaccine antigens: Antibodies in sputum of chronic obstructive pulmonary disease patientsHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2343544-2343544 [Peer Reviewed Journal]2024 GSK. Published with license by Taylor & Francis Group, LLC. 2024 GSK ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2343544 ;PMID: 38655676Full text available |
|
7 |
Material Type: Article
|
Exploring barriers to influenza vaccine uptake and recommendation among healthcare providers in the community in China: A qualitative studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2352916-2352916 [Peer Reviewed Journal]EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2352916 ;PMID: 38744298Full text available |
|
8 |
Material Type: Article
|
Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2350091-2350091 [Peer Reviewed Journal]EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2350091 ;PMID: 38757631Full text available |
|
9 |
Material Type: Article
|
Estimation of cause-specific mortality in Rakai, Uganda, using verbal autopsy 1999-2019Global health action, 2024-12, Vol.17 (1), p.2338635-2338635 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1654-9716 ;EISSN: 1654-9880 ;DOI: 10.1080/16549716.2024.2338635 ;PMID: 38717826Full text available |
|
10 |
Material Type: Article
|
SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinomaHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2350101-2350101 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2350101 ;PMID: 38738709Full text available |
|
11 |
Material Type: Article
|
Prevalence of multi-drug resistant bacteria in intensive care units at Tripoli University Hospital, Tripoli, LibyaLibyan journal of medicine, 2024-12, Vol.19 (1), p.2348235-2348235 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1993-2820 ;EISSN: 1819-6357 ;DOI: 10.1080/19932820.2024.2348235 ;PMID: 38718270Full text available |
|
12 |
Material Type: Article
|
Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case reportCancer biology & therapy, 2024-12, Vol.25 (1), p.2338644-2338644 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 1538-4047 ;EISSN: 1555-8576 ;DOI: 10.1080/15384047.2024.2338644 ;PMID: 38650446Full text available |
|
13 |
Material Type: Article
|
Human papillomavirus and occupational exposure: The need for vaccine provision for healthcare providersHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2342622-2342622 [Peer Reviewed Journal]EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2342622 ;PMID: 38771122Full text available |
|
14 |
Material Type: Article
|
Comparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survivalCancer biology & therapy, 2024-12, Vol.25 (1), p.2350249-2350249 [Peer Reviewed Journal]ISSN: 1538-4047 ;EISSN: 1555-8576 ;DOI: 10.1080/15384047.2024.2350249 ;PMID: 38722731Full text available |
|
15 |
Material Type: Article
|
Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2343552-2343552 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2343552 ;PMID: 38723789Full text available |
|
16 |
Material Type: Article
|
Knowledge about, attitudes toward and acceptance and predictors of intention to receive the mpox vaccine among cancer patients in China: A cross-sectional surveyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2337157-2337157 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2337157 ;PMID: 38644633Full text available |
|
17 |
Material Type: Article
|
Methodological issues of retrospective surveys for measuring mortality of highly clustered diseases: case study of the 2014-16 Ebola outbreak in Bo District, Sierra LeoneGlobal health action, 2024-12, Vol.17 (1), p.2331291-2331291 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1654-9716 ;EISSN: 1654-9880 ;DOI: 10.1080/16549716.2024.2331291 ;PMID: 38666727Full text available |
|
18 |
Material Type: Article
|
Benefits, challenges, and strategies related to using presumptive recommendations for HPV vaccination: A qualitative study with rural and non-rural-serving primary care professionalsHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2347018-2347018 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2347018 ;PMID: 38708779Full text available |
|
19 |
Material Type: Article
|
Comprehensive insights into COVID-19 vaccine-associated multiple evanescent white dot syndrome (MEWDS): A systematic analysis of reported casesHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2350812-2350812 [Peer Reviewed Journal]EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2350812 ;PMID: 38752704Full text available |
|
20 |
Material Type: Article
|
Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: A cross-sectional studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2345505-2345505 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2345505 ;PMID: 38724010Full text available |